The era of pulmonary surfactant from Laplace to nowadays

Acta Biomedica de l'Ateneo Parmense

Volumn 74, Issue 2, 2003, Pages 69-75+108

  Parmigiani, Stefano ^a,b   Solari, Elena ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b Unita Operativa di Cardiologia   (Italy)

Author keywords

Preterm infants; Pulmonary surfactant; Respiratory distress syndrome; Surface tension

Indexed keywords

LUCINACTANT; LUNG SURFACTANT; LUSUPULTIDE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; PLASMINOGEN; RECOMBINANT PROTEIN; SPHINGOMYELIN; SURFACTANT PROTEIN B;

AMNION FLUID; ANIMAL MODEL; ARTIFICIAL VENTILATION; CLINICAL RESEARCH; CLINICAL TRIAL; GESTATIONAL AGE; HISTORY OF MEDICINE; HUMAN; HYALINE MEMBRANE DISEASE; LUNG DEVELOPMENT; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; NEWBORN MORTALITY; NONHUMAN; PREMATURITY; RESPIRATORY DISTRESS SYNDROME; REVIEW; SURFACE TENSION;

ANIMALS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYALINE MEMBRANE DISEASE; INFANT, NEWBORN; INFANT, PREMATURE; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 0041823214     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Laplace PS. Traité de Mécanique Céleste, Crapelet, Courcier, Paris, 5° Vols., 1798-1827.
2. Jorg E. Die Foetuslunge im gebornen Kinde. Gebhardt, Grimma, 1835.
3. Citation in: Stern L, Angeles RD, Outerbridge EW, Beaudry PH Negative pressure artificial respiration: use in treatment of respiratory failure of the newborn. Can Med Assoc J 1970; 102: 595-601.
4. Drinker P, Shaw LA. An apparatus for the prolonged administration of artificial respiration. I. A design for adults and children. J Clin. Invest 1929; 7: 229-47.
5. Donald T, Lord J. Augmented respiration. Studies in atelectasis neonatorum. Lancet 1953; 1: 9-17.
6. Gregory GA, Kitterman JA, Phibbs RH, Tooley WH, Hamilton WK. Treatment of idiopathic respiratory distress syndrome with continuous positive airway pressure. New Engl J Med 1971; 58: 167-76.
7. Von Neergard K. Neue Auffassungen über einen Grundbegriff der Atemmechanik. Die Refraktionskraft der Lunge, abhängig von der Oberflachenspannung in den Alveolen. Z Gesamt Exp Med 1929; 66: 373-94.
8. Gruenwald P. Surface tension as a factor in the resistance of neonatal lungs to aeration. Am J Obstet Gynecol 1947; 53: 996-1007.
9. Thannhauser SJ, Benotti H, Boncoddo NF. Isolation and properties of hydro lecithin (dipalmitoyl lecithin) from lung, its occurrence in the sphingomyelin fraction of animal tissues. J Biol Chem 1946; 166: 669-75.
10. Macklin CC. The pulmonary alveolar mucoid film and the pneumonocytes. Lancet 1954; 1: 1099-104.
11. Gitlin D, Craig JM. The nature of the hyaline membrane in asphyxia of the newborn. Pediatrics 1956; 17: 64.
12. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959; 97: 517-23.
13. Klaus MH, Clements JA, Havel HJ. Composition of surface active material isolated from beef lung. Proc Natl Acad Sci USA 1961; 47: 1858.
14. Chu J, Clements JA, Cotton EK, Klaus MH, Sweet AY, Tooley WH. Neonatal pulmonary ischemia. Clinical and physiologic studies. Pediatrics 1967; 40: 709-82.
15. Gluck L, Motoyama EK, Smits HL, KuloVich MV. The biochemical development of surface activity in mammalian lung. I. The surface-active phospholipids; the separation and distribution of surface-active lecithin in the lung of the developing rabbit fetus. Pediatr Res 1967; 1: 237-46.
16. Gluck L, Kulovich MV, Borer RC, Brenner PH, Anderson GG, Spellacy WN. Diagnosis of the respiratory distress syndrome by amniocentesis. Am J Obstet Gynecol 1971; 109: 440-5.
17. Liggins GC. Premature delivery of fetal lambs infused with glucocorticoids. J Endocrinol 1969; 45: 515-23.
18. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972; 50: 515-25.
19. Farell PM, Wood RE. Epidemiology of hyaline membrane disease in the United States. Pediatrics 1976; 58: 167-76.
20. Hallman M, Feldman B, Gluck L. The absence of phosphatidylglycerol in surfactant. Pediatr Res 1975; 9: 396A.
21. King RJ, Clements JA. Surface actives materials from dog lung. I: method of isolation. II: composition and physiological correlation. III: thermal analysis. Am J Physiol 1972; 223: 707-14, 715-26, 727-33.
22. King RJ, Klass DJ, Gikas EG, Clements JA. Isolation of apoprotein from canine surface-active material. Am J Physiol 1973; 224: 788-95.
23. Gill J, Reiss OK. Isolation and characterization of lamellar bodies and tubular myelin from rat lung homogenates. J Cell Biol 1973; 58: 152-71.
24. Williams MC. Conversion of lamellar body membranes into tubular myelin in alveoli of fetal rat lungs. J Cell Biol 1977; 72: 260-77.
25. Ambrus CM, Choi TS, Cunnanan E, Eisenberg B, Staub HP, Weintraub DH, Courey NG, Patterson RJ, Jockin H, Pickren JW, Bross ID, Jung OS, Ambrus JL. Prevention of hyaline membrane disease with plasminogen. A cooperative study. J Am Med Ass 1977; 237: 1837-41.
26. Enhorning G, Robertson B. Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant. Pediatrics 1972; 50: 55-66.
27. Robertson B, Enhorning G. The alveolar lining of the premature newborn rabbit after pharyngeal deposition of surfactant. Lab Invest 1974; 31: 54-59.
28. Adams FH, Fujiwara T, Emmanouilides GC, Raiha N. Lung phospholipids of human fetuses and infants with and without hyaline membrane disease. J Pediatr 1970; 77: 833-41.
29. Fujiwara T, Chida S, Watabe YJ, Maeta H, Morita T, Abe T. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980; I: 55-9.
30. Cummings JJ, Holm BA, Hudak ML, Ferguson WH, Egan EA. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterms lambs. Am Rev Respir Dis 1992; 145: 999-1004.
31. Seeger W, Grube C, Gunther A, Schmidt R. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J 1993; 6: 971-7.
32. Hallman M, Merrit TA, Jarvenpaa AL, Boynton B, Mannino F, Gluck L, Moore T, Edwards D. Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective trial. J Pediatr 1985; 106: 963-9.
33. Frerking I, Gunther A, Seeger W, Pison U. Pulmonary surfactant: functions abnormalities and therapeutic options. Intensive Care Med 2001; 27: 1699-717.
34. Ten Center Study Group Ten center trial of artificial surfactant (artificial lung expanding compound) in very premature babies. Br Med J 1987; 294: 991-6.
35. Durand DJ, Clyman RI, Heymann MA, Clements JA, Mauray F, Kitterman J, Ballard P. Effects of a protein-free, synthetic surfactant on survival and pulmonary function in preterm lambs. J Pediatr 1985; 107: 775-80.
36. Giannakopoulou C, Hatzidaki E, Korakaki E, Christodoulaki M, Margari KM, Mamoulakis D. Comparative randomized study: administration of natural and synthetic surfactant to premature newborns with respiratory distress syndrome. Pediatr Int 2002; 44: 117-121.
37. Soll RF. Synthetic surfactant treatment for preterm infants with respiratory distress syndrome. (Cochrane Review). Cochrane Library, Issue 2, Oxford: Update Software, 1999.
38. Soll RF. Natural surfactant extract versus synthetic surfactant for respiratory distress syndrome. (Cochrane Review). Cochrane Library, Issue 2, Oxford: Update Software, 1999.
39. Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 1988; 82: 683-91.
40. Bevilacqua G, Halliday H, Parmigiani S, Robertson B. Randomized multicentre trial of treatment with porcine natural surfactant for moderately severe neonatal respiratory distress syndrome. The Collaborative European Multicentre Study Group. J Perinat Med 1993; 21: 329-40.
41. Bevilacqua G, Parmigiani S, Robertson B. Prophylaxis of respiratory distress syndrome by treatment with modified porcine surfactant at birth: a multicentre prospective randomized trial. J Perinat Med 1996; 24: 609-620.
42. Egberts J, de Winter JP, Sedin G, de Kleine MJ, Broberger U, van Bel F, Curstedt T, Robertson B. Comparison of prophylaxis and rescue treatment with Curosurf in neonates less than 30 weeks' gestation: a randomized trial. Pediatrics 1993; 92: 768-74.
43. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst. Rev., CD000510, 2001.
44. White RT, Damm D, Miller J, Sprat K, Schilling J, Hawgood S, Benson B, Cordell B. Isolation and characterization of the human pulmonary surfactant apoprotein gene. Nature (London) 1985; 117: 361-3.
45. Hawgood S, Benson BJ, Schilling J, Damm D, Clements JA, White RT. Nucleotide and amino acid sequences of pulmonary surfactant protein SP 18 and evidence for cooperation between SP 18 and SP 28-36 in surfactant lipid adsorption. Proc Natl Acad Sci USA 1987; 84: 66-70.
46. Cochrane CG, Revak SD, Merritt TA, Heldt GP, Hallman M, Cunningham MD, Easa D, Pramanik A, Edwards DK, Alberts MS. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153: 404-10.
47. Seeger W, Gunther A, Walmrath HD, Grimminger F, Lasch HG. Alveolar surfactant and adult respiratory distress syndrome. Pathogenetic role and therapeutic prospects. Clin Investig 1993; 71: 177-90.
48. Holm BA, Notter RH, Finkelstein JN. Surface property changes from interaction of albumin with natural lung surfactant and extracted lung lipids. Chem Phys Lipids 1985; 38: 287-98.
49. Holm BA, Notter RH. Effect of haemoglobin and cell membrane lipids on surfactant activity. J Appl Physiol 1987; 63: 1434-42.
50. Seeger W, Stoehr G, Wolf HRD, Neuhof H. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol 1985; 58: 326-38.
51. Holm BA, Enhorning G, Notter RH. A biophysical mechanism by which plasma proteins inhibit lung surfactant activity. Chem Phys Lipids 1988; 49: 49-55.
52. Friedrich W, Schmalisch G, Stevens PA, Wauer RR. Surfactant protein SP-B counteracts inhibition of pulmonary surfactant by serum proteins. Eur J Med Res 2000; 19: 277-82.
53. Seeger W, Gunther A, Thede C. Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants. Am J Physiol 1992; 262: 286-91.
54. Amirkhanian JD, Bruni R, Waring AJ, Taeusch HW. Inhibition of mixtures of surfactant lipids and synthetic sequences of surfactant proteins SP-B and SP-C. Biochim Biophys Acta 1991; 1096: 355-60.
55. Seeger W, Thede C, Gunther A, Grube C. Surface properties and sensitivity to protein-inhibition of a recombinant apoprotein C-based phospholipid mixture in vitro-comparison to natural surfactant. Biochim Biophys Acta 1991; 1081: 45-52.
56. Jobe AH. Which surfactant for treatment of respiratory-distress syndrome. Lancet 2000; 355: 1380-1.
57. Halliday HL. Controversies: synthetic or natural surfactant. The case for natural surfactant. J Perinat Med 1996; 24: 417-26.
58. Manalo E, Merritt TA, Kheiter A, Amirkhanian J, Cochrane C. Comparative effects of some serum components and proteolytic products of fibrinogen on surface tension-lowering abilities of Beractant and asynthetic peptide containing surfactant K1-4. Pediatr Res 1998; 39: 947-52.
59. Herting E, Rauprich P, Stichtenoth G, Walter G, Johansson J, Robertson B. Resistance of different surfactant preparations to inactivation by meconium. Pediatr Res 2001; 50: 44-49.